The billions dollar question is, what actually constitutes prevention, and what areas of prevention does it make sense for institutions to invest in?
The increasingly important role of payers as arbiters of what works and does not in the therapies they cover will result in payers exerting even more influence or outright acquisition of providers and point of care facilities.
This will further empower payers to move beyond risk management and create and implement prevention programs for their members to help lower overall healthcare costs, and boost profits.
But the billions dollar question is, what actually constitutes prevention, and what areas of prevention does it make sense for institutions to invest in? Likewise, for those of us that like to think and operate outside the solid lines, where should we put our focus and efforts to create amazing new technologies and platforms that can help prevent disease before it sets in?
The balance to strike is unfortunately one that bypasses an individual’s health needs, and looks at the problem holistically, through the wide-angle financial lens of large scale cost vs. benefits. Let’s take a look at a specific scenario to illustrate this point.
Continue reading on www.healthwareinternational.com.